<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="0" totalResults="6550"><SearchResults><Trial Id="9997"><Indications><Indication>Candida infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>1,3 beta glucan synthase inhibitor</Action><Action>Lanosterol-14 demethylase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Lanosterol-14 demethylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Ergosterol synthesis inhibitor</Action><Action>Fungicide</Action><Action>Systemic dermatological antifungal product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Ergosterol synthesis inhibitor</Action><Action>Fungicide</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Basilea Pharmaceutica International Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Global Development Inc</Company><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Spain</Country><Country>Philippines</Country><Country>Thailand</Country><Country>Singapore</Country><Country>Hungary</Country><Country>Lebanon</Country><Country>Israel</Country><Country>India</Country><Country>South Africa</Country><Country>Australia</Country><Country>Argentina</Country><Country>China</Country><Country>South Korea</Country><Country>Belgium</Country><Country>UK</Country><Country>France</Country><Country>Egypt</Country><Country>US</Country><Country>Brazil</Country><Country>Switzerland</Country><Country>New Zealand</Country><Country>Canada</Country><Country>Turkey</Country><Country>Mexico</Country><Country>Malaysia</Country><Country>Chile</Country><Country>Russian Federation</Country><Country>Italy</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2015-03-03T00:00:00Z</DateEnd><DateStart>2007-03-08T00:00:00Z</DateStart><Identifiers><Identifier>2006-003951-18</Identifier><Identifier>9766-CL-0105</Identifier><Identifier>ACTIVE</Identifier><Identifier>CTRI/2012/01/002351</Identifier><Identifier>NCT00413218</Identifier><Identifier>NCT00444366</Identifier><Identifier>WSA-CS-008</Identifier></Identifiers><InterventionsControlDisplay><Intervention>caspofungin alone</Intervention><Intervention>voriconazole alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>isavuconazonium chloride/sulfate (intravenous), Basilea/Astellas alone</Intervention><Intervention>isavuconazonium chloride/sulfate (oral), Basilea/Astellas alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>450</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this phase III, double-blind, randomized, ACTIVEÂ study was to compare the safety and efficacy of isavuconazole (ASP-9766, ISA) versus caspofungin ( Cancidas , CAS) followed by voriconazole ( VFend , VRC) in the treatment of candidemia and other invasive Candida infections. Based on the DRC assessments of positive clinical and mycological responses, as well as no need for alternative systemic antifungal therapy (SAT), the primary endpoint, success rate of overall response</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Candida infection - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Candida infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Candida infection - Assessment of Microbiological Response</EndpointIndex><EndpointIndex>Candida infection - Assessment of Mortality/Death Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ACTIVE: Isavuconazole (BAL-8557) in the Treatment of Candidemia and Other Invasive Candida Infections</TitleDisplay><PatientSegmentTerms><PatientSegment>Candida infection - Subjects with Invasive Candidiasis - Subjects with candidemia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-03-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>95 Months</TrialDuration><NumberOfSites>301</NumberOfSites><ContactNames><Name>Clinical Trial Support</Name><Name>David Lye Chian Boon</Name><Name>Ernest Wang Chee Meng</Name><Name>Medical Director</Name><Name>ND</Name><Name>Wijaya Limin</Name><Name>contact@nl.astellas.com</Name></ContactNames></Trial><Trial Id="99945"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Europe Ltd</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Austria</Country><Country>UK</Country><Country>Italy</Country><Country>Greece</Country><Country>Spain</Country><Country>Portugal</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2014-08-31T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>ASCEND</Identifier><Identifier>CCRN 840 (Peripheral Neuropathic Pain)</Identifier><Identifier>NCT01737294</Identifier><Identifier>QTZ-EC-0003</Identifier><Identifier>UKCRN 12588</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>429</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This non-interventional study was to evaluate the efficacy, tolerability, health related quality of life and use of health resources associated with Qutenza treatment when Qutenza is used in standard clinical practice [ 1433705 ]. The patients primary diagnosis of peripheral neuropathic pain (PNP) would be classified into subtypes: post-herpetic neuralgia (PHN); HIV-associated neuropathy (HIV-AN); neuropathic back pain; cancer-related neuropathic pain; post-operative and post-traumatic neuropathic</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ASCEND: Observation of the use of Qutenza in Standard Clinical Practice</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>50</NumberOfSites><ContactNames><Name>Company Medical Expert</Name></ContactNames></Trial><Trial Id="99922"><Indications><Indication>Familial amyloid neuropathy</Indication><Indication>Myocardial disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Amyloid protein deposition inhibitor</Action><Action>TTR gene inhibitor</Action><Action>Transthyretin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antisense oligonucleotide inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oligonucleotide antisense</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>GlaxoSmithKline plc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ionis Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Brazil</Country><Country>US</Country><Country>Italy</Country><Country>Portugal</Country><Country>Bulgaria</Country><Country>New Zealand</Country><Country>Spain</Country><Country>UK</Country><Country>Germany</Country><Country>Argentina</Country></Countries><DateChangeLast>2019-06-26T00:00:00Z</DateChangeLast><DateEnd>2017-11-07T00:00:00Z</DateEnd><DateStart>2013-03-15T00:00:00Z</DateStart><Identifiers><Identifier>2012-001831-30</Identifier><Identifier>ISIS 420915-CS2</Identifier><Identifier>NCT01737398</Identifier><Identifier>NEURO-TTR</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Chill</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Glomerulonephritis</Indication><Indication>Intracranial hemorrhage</Indication><Indication>Nausea</Indication><Indication>Renal insufficiency</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>inotersen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>173</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase III, pivotal, 15-month, double-blind, placebo-controlled, international study was to evaluate the efficacy and safety of IONIS-TTRRx (inotersen) given for 65 weeks in patients with familial amyloid polyneuropathy (FAP) [ 1530405 ], [ 1600925 ], [ 1609790 ], [ 1766279 ], [ 1927401 ], [ 1943708 ], [ 1970866 ], [ 1977255 ], [ 1977874 ], [ 1978744 ], [ 1995708 ], [ 2016937 ], [ 2026008 ], [ 2040714 ], [ 2053248 ], [ 2065868 ], [ 2061819 ]. The purpose of this study was to</Teaser><TrialCategories><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NEURO-TTR: Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Subjects with gene variants - TTR_HUMAN_Mutation</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Neuropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Amyloid </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Retinol-binding protein 4 </BiomarkerName><BiomarkerName> Transthyretin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-03-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>55 Months</TrialDuration><NumberOfSites>30</NumberOfSites><ContactNames><Name>Dr. Josep GÃ¡mez</Name><Name>John L. Berk</Name><Name>Matt R. Buck</Name></ContactNames></Trial><Trial Id="99864"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Dipeptidyl peptidase IV inhibitor</Action><Action>Sodium glucose transporter-2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>DPP IV inhibitor antidiabetic product</Action><Action>Hypoglycemic agent</Action><Action>Vulnerary agent</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>DPP IV inhibitor antidiabetic product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Eli Lilly &amp; Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Norway</Country><Country>India</Country><Country>US</Country><Country>Australia</Country><Country>Russian Federation</Country><Country>Canada</Country><Country>France</Country><Country>Philippines</Country><Country>El Salvador</Country><Country>Taiwan</Country><Country>Italy</Country><Country>South Korea</Country><Country>Brazil</Country><Country>Bulgaria</Country><Country>New Zealand</Country><Country>North Korea</Country><Country>Spain</Country></Countries><DateChangeLast>2017-10-27T00:00:00Z</DateChangeLast><DateEnd>2015-03-31T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>1275.9</Identifier><Identifier>2012-002270-31</Identifier><Identifier>NCT01734785</Identifier></Identifiers><IndicationsAdverse><Indication>Genital tract infection</Indication><Indication>Hypersensitivity</Indication><Indication>Hypoglycemia</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>linagliptin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>empagliflozin + linagliptin (oral, type 2 diabetes), Boehringer/Eli Lilly alone</Intervention><Intervention>empagliflozin alone</Intervention><Intervention>group 1 alone</Intervention><Intervention>group 2 alone</Intervention><Intervention>linagliptin + placebo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>607</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase III, randomized, double-blind, parallel-group, 24-week study was to evaluate efficacy and safety of empagliflozin + linagliptin (Glyxambi) 10 mg qd + 5 mg and 25 mg qd + 5 mg po compared to placebo, all administered as fixed dose combinations, in patients with type 2 diabetes mellitus and insufficient glycemic control after 16 weeks treatment with linagliptin 5 mg qd on metformin background therapy.This trial was to compare the use of the twoÂ differentÂ doses of empagliflozin</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety And Efficacy Of The Combination Of Empagliflozin And Linagliptin Compared To Linagliptin Alone Over 24 Weeks In Patients With Type 2 Diabetes</TitleDisplay><PatientSegmentTerms><PatientSegment>Non-insulin dependent diabetes - Subjects Inadequately Controlled with Oral Hypoglycemic Agents</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Monotherapy - Subjects only on metformin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Magnesium </BiomarkerName><BiomarkerName> Phosphate </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> Waist circumference</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>104</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name><Name>QRPE PSC CT Information Disclosure</Name></ContactNames></Trial><Trial Id="99814"><Indications><Indication>Aggression</Indication><Indication>Agitation</Indication><Indication>Alzheimers disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Amyloid protein deposition inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Neuroprotectant</Action><Action>Psychomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Elan Pharmaceuticals Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Transition Therapeutics Ireland Ltd</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Spain</Country><Country>Canada</Country><Country>US</Country><Country>UK</Country></Countries><DateChangeLast>2018-06-08T00:00:00Z</DateChangeLast><DateEnd>2015-05-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-004299-20</Identifier><Identifier>ELND005-AG201</Identifier><Identifier>HARMONY-AD</Identifier><Identifier>NCT01735630</Identifier><Identifier>UKCRN 13705</Identifier></Identifiers><IndicationsAdverse><Indication>Agitation</Indication><Indication>Diarrhea</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>ELND-005 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>350</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary purpose of this 12-week, two-arm, randomized, double-blind, placebo-controlled study was to determine whether ELND-005 would be effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease (AD) [ 1647150 ], [ 1672734 ]. The main objective of this trial was to evaluate the efficacy of ELND-005 treatment compared with placebo in reducing the severity of agitation and aggression at 12 weeks; to evaluate the safety and tolerability of the ELND-005 dosing</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Neuropsychological Function - Assessment by Mini-Mental State Examination (MMSE)</EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Psychiatric Symptoms - Assessment by Neuropsychiatric Inventory (NPI)</EndpointIndex><EndpointIndex>Alzheimers disease - Cognitive, Global and Functional Assessments - Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS CGIC) score</EndpointIndex><EndpointIndex>Alzheimers disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Activities of Daily Living scale (ADL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HARMONY-AD: Efficacy and Safety Study of ELND-005 as a Treatment for Agitation and Aggression in Alzheimer's Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Alzheimers disease - Subjects with Moderate Alzheimer's Disease</PatientSegment><PatientSegment>Alzheimers disease - Subjects with Probable Diagnosis of Alzheimer's Disease</PatientSegment><PatientSegment>Alzheimers disease - Subjects with Severe Alzheimer's Disease</PatientSegment><PatientSegment>Alzheimers disease - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>74</NumberOfSites><ContactNames><Name>Europe: Lisa Parsons</Name><Name>Global Project Management</Name><Name>US and Canada: Call Center</Name></ContactNames></Trial><Trial Id="99811"><Indications><Indication>Molybdenum cofactor deficiency</Indication></Indications><CompaniesSponsor><Company>Alexion Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Netherlands</Country><Country>Japan</Country><Country>Saudi Arabia</Country><Country>Spain</Country><Country>Germany</Country><Country>US</Country><Country>Israel</Country><Country>UK</Country><Country>Italy</Country><Country>Malaysia</Country><Country>Tunisia</Country><Country>Canada</Country><Country>Turkey</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2013-08-31T00:00:00Z</DateStart><Identifiers><Identifier>ALX-MCD-502</Identifier><Identifier>NCT01735188</Identifier></Identifiers><PatientCountEnrollment>65</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to characterize the natural history of MoCD type A in terms of survival. The secondary objectives were: Evaluate blood and urine for biochemical markers. Evaluate head circumference, seizure activity and neurological outcomes. To evaluate brain MRI. To compare blood and urine analysis, head circumference, seizure activity and neurological outcomes to MRI findings.</Teaser><TrialCategories><Category>Pathophysiology</Category></TrialCategories><EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Biomarkers - Assessment of S-sulfo-cysteine (SSC)</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Biomarkers - Assessment of urine and blood biomarkers</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Biomarkers - Assessment of xanthine</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Renal Function - Assessment of uric acid</EndpointIndex><EndpointIndex>Other metabolic disease - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TitleDisplay>A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies</TitleDisplay><PatientSegmentTerms><PatientSegment>Other metabolic disease - Subjects with comorbid conditions - Subjects co-morbid with Molybdenum cofactor deficiency</PatientSegment><PatientSegment>Other metabolic disease - Subjects with comorbid conditions - Subjects with isolated sulfite oxdiase deficiency</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Head circumference </BiomarkerName><BiomarkerName> S-Sulphocysteine </BiomarkerName><BiomarkerName> Sulfite oxidase, mitochondrial </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> Xanthine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>32</NumberOfSites></Trial><Trial Id="99776"><Indications><Indication>Multiple myeloma</Indication></Indications><ActionsPrimaryInterventionsControl><Action>26S proteasome complex inhibitor</Action><Action>Proteasome inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>26S proteasome complex inhibitor</Action><Action>Proteasome inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Apoptosis stimulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Antiviral</Action><Action>Apoptosis stimulator</Action><Action>Immunomodulator</Action><Action>TNF alpha synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Celgene Corp</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Australia</Country><Country>Israel</Country><Country>Italy</Country><Country>Denmark</Country><Country>Argentina</Country><Country>Ireland</Country><Country>UK</Country><Country>Puerto Rico</Country><Country>Austria</Country><Country>Japan</Country><Country>Sweden</Country><Country>Poland</Country><Country>Russian Federation</Country><Country>Spain</Country><Country>Turkey</Country><Country>Norway</Country><Country>South Korea</Country><Country>Portugal</Country><Country>Finland</Country><Country>France</Country><Country>US</Country><Country>Greece</Country><Country>Canada</Country><Country>Germany</Country><Country>Taiwan</Country></Countries><DateChangeLast>2019-05-28T00:00:00Z</DateChangeLast><DateEnd>2022-05-01T00:00:00Z</DateEnd><DateStart>2013-01-07T00:00:00Z</DateStart><Identifiers><Identifier>2014-000268-17</Identifier><Identifier>CC-4047-MM-007</Identifier><Identifier>DRKS00008025</Identifier><Identifier>MM-007</Identifier><Identifier>NCT01734928</Identifier><Identifier>OPTIMISMM</Identifier><Identifier>UKCRN 18756</Identifier></Identifiers><IndicationsAdverse><Indication>Deep vein thrombosis</Indication><Indication>Infectious disease</Indication><Indication>Lung embolism</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including Velcade + dexamethasone , bortezomib , dexamethasone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including bortezomib , dexamethasone , pomalidomide , pomalidomide + Velcade + dexamethasone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>559</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this phase III, randomized, open-label, international clinical study was to compare the efficacy and safety of the combination of pomalidomide , bortezomib (Velcade) and low dose dexamethasone (POM + BTZ + LD-DEX) to the combination of bortezomib and low dose dexamethasone (BTZ + LD-DEX) in patients with relapsed/refractory multiple myeloma [ 1666142 ], [ 1984669 ], [ 2003039 ], [ 2033153 ], [ 2040804 ], [ 2155172 ]. This study would also assess how safe the combination of pomalidomide</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)</EndpointIndex><EndpointIndex>Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OPTIMISMM: Safety and Efficacy of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</TitleDisplay><PatientSegmentTerms><PatientSegment>Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma</PatientSegment><PatientSegment>Multiple myeloma - Subjects with Treatment Resistant Disease - Subjects with chemotherapy resistant disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Beta-2-microglobulin </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Free light chains </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Immunoglobulins </BiomarkerName><BiomarkerName> Myeloma protein </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2022-05-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>111 Months</TrialDuration><NumberOfSites>217</NumberOfSites><ContactNames><Name>Amine Bensmaine, MD</Name><Name>ClinicalTrialDisclosure</Name><Name>Dr NCRN Coordinating Centre</Name><Name>Luo Ling Ling</Name><Name>Paul Richardson, M.D</Name><Name>RJ Corman</Name></ContactNames></Trial><Trial Id="99719"><Indications><Indication>Allergic conjunctivitis</Indication><Indication>Allergic rhinitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Allergen</Action><Action>Immunomodulator</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Laboratorios Leti SL</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-08-12T00:00:00Z</DateChangeLast><DateEnd>2013-03-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-001699-12</Identifier><Identifier>6078-PG-PSC-193</Identifier><Identifier>NCT01734265</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Parietaria Judaica-containing vaccine (sc, allergic rhinitis/rhinoconjunctivitis), Laboratorios Leti alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of immunoglobulin levels</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea (2000 DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica (2000 DPP/ml)</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>AranzazuÂ  Minano</Name><Name>JoaquÃ­n Quiralte, Dr</Name><Name>Luis Angel Navarro, Dr</Name><Name>MariaÂ  Gomez</Name><Name>Pedro Guardia, Dr</Name><Name>Santiago Nevot, Dr</Name></ContactNames></Trial><Trial Id="99619"><Indications><Indication>Metastatic breast cancer</Indication><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Spanish Breast Cancer Research Group</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-02-15T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>BRECOL</Identifier><Identifier>GEI-BEV-2011-02</Identifier><Identifier>GEICAM/2011-04</Identifier><Identifier>NCT01733628</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bevacizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>137</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. A total of 137 metastatic breast cancer patients or metastatic colorectal cancer. The hypertension will be evaluated as a predictor of efficacy of bevacizumab associated with chemotherapy, in terms of progression-free survival (main endpoint).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Biopsy/Cytology/Histology</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Breast tumor - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Organ Function</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Pharmacogenomic Evaluation</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interleukin-6 (IL-6)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Vascular Endothelial Function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BRECOL: Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Metastatic Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Treatment Naive Subjects</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Angiotensin converting enzyme </BiomarkerName><BiomarkerName> Angiotensinogen </BiomarkerName><BiomarkerName> Beta2-adrenergic receptor </BiomarkerName><BiomarkerName> Beta3-adrenergic receptor </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> GNAS complex locus </BiomarkerName><BiomarkerName> Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Placenta growth factor </BiomarkerName><BiomarkerName> VEGF/SEMA ratio </BiomarkerName><BiomarkerName> Vascular endothelial growth factor receptor-1 </BiomarkerName><BiomarkerName> Vascular endothelial growth factors </BiomarkerName><BiomarkerName> von Willebrand factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Alvaro RodrÃ­guez Lescure</Name><Name>AlvaroÂ Lescure</Name><Name>Antonio AntÃ³n, PhD., MD.</Name><Name>AntonioÂ Anton</Name><Name>Eva Carrasco Carrascal</Name><Name>EvaÂ Carrascal</Name><Name>JoseÂ Chacon</Name><Name>JosÃ© I. ChacÃ³n, PhD., MD.</Name><Name>JosÃ© Ignacio ChacÃ³n, PhD., MD.</Name><Name>LourdesÂ Calvo</Name><Name>MiguelÂ Segui</Name><Name>Ruth Campo de la Fuente</Name><Name>RuthÂ Fuente</Name></ContactNames></Trial><Trial Id="99593"><Indications><Indication>Juvenile rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-6 receptor antagonist</Action><Action>IL-6 receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Antihypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Productos Roche, S.A. de C.V.</Company></CompaniesCollaborator><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>Spain</Country><Country>Sweden</Country><Country>Russian Federation</Country><Country>UK</Country><Country>Germany</Country><Country>Mexico</Country><Country>Argentina</Country><Country>Israel</Country><Country>US</Country><Country>Italy</Country></Countries><DateChangeLast>2019-06-06T00:00:00Z</DateChangeLast><DateEnd>2019-09-07T00:00:00Z</DateEnd><DateStart>2013-06-10T00:00:00Z</DateStart><Identifiers><Identifier>2012-000444-10</Identifier><Identifier>MCRN214 (WA28029)</Identifier><Identifier>NCT01734382</Identifier><Identifier>UKCRN 13561</Identifier><Identifier>WA28029</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tocilizumab (intravenous), Roche/Chugai alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This open-label, phase IV study will evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of RoActemra/Actemra ( tocilizumab ) in reduced dose frequency in patients with adequately controlled systemic juvenile idiopathic arthritis who have experienced a laboratory abnormality on twice-weekly tocilizumab dosing. The primary objectives are: Efficacy: To explore the efficacy of tocilizumab in reduced dosing frequency regimens using Juvenile Arthritis Disease Activity</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of adverse events</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of disease flare</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Patient Global Assessment of Disease Activity</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Physician Global Assessment of Disease Activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)</TitleDisplay><PatientSegmentTerms><PatientSegment>Rheumatoid arthritis - Juvenile Rheumatoid Arthritis (JRA)</PatientSegment><PatientSegment>Rheumatoid arthritis - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Interleukin-6</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-07T00:00:00Z</PrimaryCompletionDate><TrialDuration>74 Months</TrialDuration><NumberOfSites>29</NumberOfSites><ContactNames><Name>CarlaÂ Owen</Name><Name>Clinical Trials</Name><Name>EileenÂ Baildam</Name><Name>Karina Santamaria</Name><Name>Monica Lopez Navarro</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial></SearchResults></trialResultsOutput>